— Know what they know.
Not Investment Advice
Also trades as: FLDM (NASDAQ) · $vol 4M

LAB NASDAQ

Standard BioTools Inc.
1W: +0.7% 1M: +10.6% 3M: -16.1% YTD: -41.4% 1Y: -41.8% 3Y: -74.0% 5Y: -88.7%
$0.74
+0.02 (+2.25%)
 
Weekly Expected Move ±6.1%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Medical - Specialties · Tech Score Neutral · Power 49 · $291.5M mcap · 43M float · 6.63% daily turnover · Short 47% of daily vol

Supply Chain Overview

23 relationships
21
As Filer
counterparties named
2
As Counterparty
mentioned by others
3
Rel. Types
2022-01-24
Earliest Filing
2026-01-30
Latest Filing
investor: 18 acquirer: 2 target: 1

Counterparties (Filed by LAB)

21 relationships

Companies named in LAB's SEC 8-K filings as business counterparties.

Counterparty Ticker Relationship Summary Filing Date SEC
Illumina, Inc. ILMN acquirer Acquired all equity interests of SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd for up to 2026-01-30 View
Illumina, Inc. ILMN acquirer Acquired all equity interests of SomaLogic, Inc., Sengenics Corporation LLC, and Sengenics Corporation Pte Ltd for up to 2025-06-23 View
SomaLogic, Inc. SLM target Target company in the merger with Standard BioTools Inc. 2024-01-05 View
Casdin Private Growth Equity Fund II, L.P. — investor Purchaser of Series B-1 Convertible Preferred Stock and lender in the Casdin Loan Agreement 2022-04-05 View
Casdin Partners Master Fund, L.P. — investor Purchaser of Series B-1 Convertible Preferred Stock and lender in the Casdin Loan Agreement 2022-04-05 View
Viking Global Opportunities Illiquid Investments Sub-Master LP VIK investor Purchaser of Series B-2 Convertible Preferred Stock and lender in the Viking Loan Agreement 2022-04-05 View
Viking Global Opportunities Drawdown (Aggregator) LP VIK investor Purchaser of Series B-2 Convertible Preferred Stock and lender in the Viking Loan Agreement 2022-04-05 View
Caligan Partners LP — investor Entered into a support agreement with Fluidigm Corporation regarding board appointments and proxy voting. 2022-03-29 View
Casdin Private Growth Equity Fund II, L.P. — investor Signatory to the Series B-1 Convertible Preferred Stock Purchase Agreement. 2022-03-29 View
Casdin Partners Master Fund, L.P. — investor Signatory to the Series B-1 Convertible Preferred Stock Purchase Agreement. 2022-03-29 View
Viking Global Opportunities Illiquid Investments Sub-Master LP VIK investor Signatory to the Series B-2 Convertible Preferred Stock Purchase Agreement. 2022-03-29 View
Viking Global Opportunities Drawdown (Aggregator) LP VIK investor Signatory to the Series B-2 Convertible Preferred Stock Purchase Agreement. 2022-03-29 View
Casdin Private Growth Equity Fund II, L.P. — investor Counterparty to Series B-1 Convertible Preferred Stock Purchase Agreement 2022-03-28 View
Casdin Partners Master Fund, L.P. — investor Counterparty to Series B-1 Convertible Preferred Stock Purchase Agreement 2022-03-28 View
Viking Global Opportunities Illiquid Investments Sub-Master LP VIK investor Counterparty to Series B-2 Convertible Preferred Stock Purchase Agreement 2022-03-28 View
Viking Global Opportunities Drawdown (Aggregator) LP VIK investor Counterparty to Series B-2 Convertible Preferred Stock Purchase Agreement 2022-03-28 View
Casdin Private Growth Equity Fund II, L.P. — investor Lender and purchaser of Series B-1 Convertible Preferred Stock 2022-01-24 View
Casdin Partners Master Fund, L.P. — investor Purchaser of Series B-1 Convertible Preferred Stock 2022-01-24 View
Viking Global Investors LP VIK investor Lender and purchaser of Series B-2 Convertible Preferred Stock 2022-01-24 View
Viking Global Opportunities Illiquid Investments Sub-Master LP VIK investor Purchaser of Series B-2 Convertible Preferred Stock 2022-01-24 View
Viking Global Opportunities Drawdown (Aggregator) LP VIK investor Purchaser of Series B-2 Convertible Preferred Stock 2022-01-24 View

Mentioned As Counterparty

2 mentions

Other companies that named LAB in their SEC 8-K filings.

Filed By Relationship Summary Filing Date SEC
ILMN ILLUMINA, INC. acquirer Target of acquisition for aptamer-based and functional proteomics business 2026-01-30 View
ILMN ILLUMINA, INC. target Target of acquisition for aptamer-based and functional proteomics business 2025-06-23 View
Recent 8-K Filings (20)
Filing Date Description Type SEC
2026-09-30 Material Agreement; Termination of Agreement; Regulation FD; Exhibits Agreement View
2026-08-05 Earnings Release; Regulation FD; Exhibits View
2026-07-29 Exhibits View
2026-07-28 Material Agreement; Regulation FD; Exhibits Agreement View
2026-07-24 Delisting Notice View
2026-06-18 Officer/Director Change; Shareholder Vote; Exhibits View
2026-06-08 Material Agreement; Unregistered Equity Sales; Change in Control; Officer/Director Change; Regulatio Agreement View
2026-06-05 Other Events View
2026-06-03 Officer/Director Change View
2026-05-28 Officer/Director Change; Exhibits View
2026-05-05 Earnings Release; Regulation FD; Exhibits View
2026-04-24 Delisting Notice View
2026-02-24 Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex View
2026-02-05 Financial Statements and Exhibits View
2026-01-30 Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition; R Acquisition View
2026-01-08 Results of Operations and Financial Condition; Financial Statements and Exhibits View
2025-11-04 Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex View
2025-09-17 Costs Associated with Exit or Disposal Activities View
2025-09-03 Costs Associated with Exit or Disposal Activities View
2025-08-11 Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex View
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms